Coagulation factor II (F2)

Where the papers sit

10 papers from the last 6 months study Coagulation factor II (F2) directly · updated from PubMed 3 Nov 2026

• Thrombin-Linked Cancer and Thrombosis

  Thrombin signaling links coagulation to tumor progression, vascular infarction, and systemic prothrombotic states. PAR1 signaling regulates Top1 in breast cancer, tying inflammation to progression. Thrombin-conjugated CpG nanogels seek tumor-vessel infarction with immune activation, while abdominal fat measures track sex-specific thrombosis risk. DNA nanostructures instead use thrombin activation for ratiometric ECL/SERS detection, leaving clinical translation and biosafety open.

  4 papers · 40%

• Thrombin Inhibitor Discovery

  Allosteric and reversible thrombin inhibitors are being pursued alongside peptide and plant-derived serine-protease inhibitors. AI-guided screening and DCC discovery emphasize binding potency, including a reversible sub-picomolar inhibitor. Mechanistic modeling and mass spectrometry support target engagement, while macrocyclic 6-mercaptopurine compounds extend inhibition toward combined skin-cancer treatment. Cellular efficacy, selectivity, and safety remain less established than in vitro potency.

  4 papers · 40%

• Others — Inflammatory Injury Therapies

  Snakebite edema and ischemic-stroke injury are addressed through distinct anti-inflammatory strategies rather than a single therapeutic program. Protobothrops mucrosquamatus work attributes persistent edema to mismatch between phospholipase A2 activity and antivenom affinity. Curcumae Rhizoma research targets COX-2-mediated neuroinflammation and neuroprotection after ischemia. The shared emphasis is inflammatory tissue damage, with no clear convergence in mechanism or clinical direction.

  2 papers · 20%